Publisher's Synopsis
This symposium report is a valuable contribution to the scientific discussion on the objective and subjective criteria used to diagnose Benign Prostatic Hypertrophy (BPH). It also provides an evaluation of the influence of therapy on the disease. The papers presented are based on internationally validated parameters and mostly address issues that are of importance for improving the patients' quality of life. In this context special attention is paid to the treatment options of the a1-blocker, alfuzosin. The results of two observational trials on the effects of this drug show that it cannot only influence symptoms and objective parameters directly related to the disease itself, but that it can also improve the well-being of patients. A review of current medical treatment of BPH completes this timely publication.
